Evidence map›Paper›PMID 36813084›Full record

ArticleContemporary clinical trials2023

A relational agent for treating substance use in adults: Protocol for a randomized controlled trial with a psychoeducational comparator.

Judith J Prochaska, Erin A Vogel, Amy Chieng, Michael Baiocchi, Sarah Pajarito, Maddison Pirner, Alison Darcy, Athena Robinson

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04925570 (Woebot for Substance Use Disorders Phase 2 RCT), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04925570 phase2completednot on this map

Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use

TypeinterventionalSponsorWoebot HealthRan2022 to 2023Enrolled258ConditionsAlcohol Use Disorder (AUD), Substance Use DisordersArmsW-SUDs, Digitally-delivered Psychoeducation
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Mitigating fraud in a fully decentralized clinical trial of a digital health intervention.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2025
    Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Judith J ProchaskaStanford Prevention Research Center, Department of Medicine, School of Medicine, Stanford University, United States of America. Electronic address: jpro@stanford.edu.
Erin A VogelStanford Prevention Research Center, Department of Medicine, School of Medicine, Stanford University, United States of America.
Amy ChiengStanford Prevention Research Center, Department of Medicine, School of Medicine, Stanford University, United States of America.
Michael BaiocchiDepartment of Epidemiology & Population Health, School of Medicine, Stanford University, United States of America.
Sarah PajaritoWoebot Health, United States of America.
Maddison PirnerWoebot Health, United States of America.
Alison DarcyWoebot Health, United States of America.
Athena RobinsonWoebot Health, United States of America.

Funding

RCT of Woebot for Substance Use DisordersR44DA048712 · NIDA · WOEBOT LABS, INC. · PI ROBINSON, ATHENA · 2019 to 2021
$1.6M
NIDA NIH HHS R44 DA048712
6 · The paper itself

Abstract

backgroundSubstance use disorders (SUDs) are prevalent and compromise health and wellbeing. Scalable solutions, such as digital therapeutics, may offer a population-based strategy for addressing SUDs. Two formative studies supported the feasibility and acceptability of the relational agent Woebot, an animated screen-based social robot, for treating SUDs (W-SUDs) in adults. Participants randomized to W-SUDs reduced their substance use occasions from baseline to end-of-treatment (EOT) relative to a waitlist control.

objectiveTo further develop the evidence base, the current randomized trial extends follow-up to 1-month post-treatment and will test the efficacy of W-SUDs relative to a psychoeducational control.

methodsThis study will recruit, screen, and consent 400 adults online reporting problematic substance use. Following baseline assessment, participants will be randomized to 8 weeks of W-SUDs or a psychoeducational control. Assessments will be conducted at weeks 4, 8 (EOT), and 12 (1-month post-treatment). Primary outcome is past-month number of substance use occasions, summed across all substances. Secondary outcomes are number of heavy drinking days, the percent of days abstinent from all substances, substance use problems, thoughts about abstinence, cravings, confidence to resist substance use, symptoms of depression and anxiety, and work productivity. If significant group differences are found, we will explore moderators and mediators of treatment effects.

conclusionsThe current study builds upon emerging evidence of a digital therapeutic for reducing problematic substance use by examining sustained effects and testing against a psychoeducational control condition. If efficacious, the findings have implications for scalable mobile health interventions for reducing problematic substance use.

trial registrationNCT04925570.

Indexed as

RoboticsSubstance-Related DisordersAdultAnxiety DisordersHumansRandomized Controlled Trials as TopicSocial InteractionArtificial intelligenceRandomized controlled trialRelational conversational agentSubstance-related disorders

Identifiers

PMID36813084
PMCPMC10065942

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.